Share: 
Status: 
Active
Rating: 
No votes yet
0

On Demand 2016 What to Do When Asthma Does Not Respond to Step 3 Treatment (MOC)

Course description

You can earn up to 1.25 AMA PRA Category 1 Credit(s)™. This activity has also been designated by the ABAI for 1.25 MOC Part II Self-Assessment credits. 

This session will focus on the biologic characteristics of severe asthma and ACOS and why patients fail to respond to traditional therapies. Newer management strategies will be discussed, including pharmacologic therapies and the use of bronchial thermoplasty.

Release Date: 12/01/2016
Expiration Date: 11/30/2019

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning objectives: 
  • Recognize the asthma-COPD overlap syndrome and differences between the two separate conditions
  • Discuss which patients would best respond to anticholinergic and phosphodiesterase inhibitor therapy
  • Describe risks and benefits of therapy with bronchial thermoplasty
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Attendance
  • 1.25 MOC
Additional information
Disclosure: 
  • Todd A. Mahr, MD, FACAAI, Moderator – Consultant/Advisor: Meda, Teva; Speaker: Aerocrine, AstraZeneca, GlaxoSmithKline, Meda, Merck, Teva; Supported/Contracted Research: AstraZeneca
  • R. Stokes Peebles, MD, FACAAI – Nothing to disclose
  • Stephen Peters, MD, PhD – Consultant/Advisor: Aerocrine, Array BioPharma, AstraZeneca, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Novartis, Ono, Sunovion, Teva
  • Mario Castro, MD, MPH – Consultant/Advisor: Boston Scientific, Genentech, GlaxoSmithKline, Neostem, Holaira, Teva; Speaker: Boehringer Ingelheim, Boston Scientific, Genentech, Teva; Supported/Contracted Research: Amgen, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Johnson & Johnson, MedImmune, Novartis, Pfizer, Sanofi, Teva, Vectura, Sparo, INC
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Attendance
  • 1.25 MOC
Course opens: 
12/01/2016
Course expires: 
11/30/2019
Cost:
$39.00
Please login or create an account to take this course.

Payment required

You must purchase this course.